Dr. Banda is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E, G3630
Seattle, WA 98109
Summary
- Dr. Kalyan Banda is an oncologist in Seattle at the Fred Hutchinson Cancer Center and UW Medicine. He received his medical degree from Christian Medical College Vellore and has been in practice 9 years. He specializes in breast and gynecologic cancer, clinical trials including phase I/ experimental therapeutics. He is a translational researcher with expertise in precision medicine.
Education & Training
- Fred Hutchinson Cancer Research CenterPost-Doctoral Fellowship, 2016 - 2018
- University of WashingtonFellowship, Hematology and Medical Oncology, 2014 - 2018
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2011 - 2014
- UC San Diego Medical Center - HillcrestPost-Doctoral Fellowship, 2009 - 2011
- Christian Medical College VelloreClass of 2008
Certifications & Licensure
- CA State Medical License 2013 - Present
- AK State Medical License 2022 - 2026
- WA State Medical License 2014 - 2026
- ID State Medical License 2022 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Career Development Award American Society of Clinical Oncology, 2020
- Young Investigator Award American Society of Clinical Oncology, 2018
- Department of Defense Prostate Cancer Research Program- Early Investigator Research Award (declined) 2018
- Join now to see all
Publications & Presentations
PubMed
- Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial ca...Kan Yonemori, Valentina Boni, Kim Gun Min, Tarek M Meniawy, Janine Lombard
Gynecologic Oncology. 2024-12-01 - 16 citationsExtraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing.Heidi J Gray, Payel Chatterjee, Rachele Rosati, Lauren R Appleyard, Grace J Durenberger
NPJ Precision Oncology. 2023-05-18 - 4 citationsDiagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays.Niklas Krumm, Nithisha S Khasnavis, Marc Radke, Kalyan Banda, Helen R Davies
JCO Precision Oncology. 2023-05-01
Journal Articles
- Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to PARP Inhibitor TherapyBanda K, Swisher E, Gray H, Pritchard CC, Gadi VK, JCO Precision Oncology, 1/1/2018
- A red meat-derived glycan promotes inflammation and cancer progressionSamraj AN, Pearce OM, Läubli H, Crittenden AN, Bergfeld AK, Banda K, Gregg CJ, Bingman AE, Secrest P, Diaz SL, Varki NM, Varki A, Proc Natl Acad Sci, 1/13/2015
- Jehovah’s WitnessBanda K, The Human Condition, 1/1/2013
- Join now to see all
Abstracts/Posters
- Characterizing and Targeting Aberrant mRNA Translation in Advanced Prostate CancerBanda K, FHCRC HB Retreat, 1/1/2017
- Dissecting the Interface Between Androgen Signaling and mRNA Translation in Advanced Prostate CancerBanda K, PPCR/ SPORE, 1/1/2017
- Dissecting the interface between androgen signaling and mRNA translation in advanced prostate cancerBanda K, K Yang K, Nelson P, Hsieh A, Multi institutional Prostate SPORE retreat, 1/1/2017
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: